From what 0 stock analysts predict, the share price for Gemini Therapeutics, Inc. (GMTX) might decrease by 100% in the next year. This is based on a 12-month average estimation for GMTX. Price targets go from $ to $. The majority of stock analysts believe GMTX is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
GMTX is a stock in which has been forecasted to be worth $ as an average. On the higher end, the forecast price is $ USD by from Goldman Sachs and on the lower end GMTX is forecasted to be $ by from Goldman Sachs.
These are the latest 20 analyst ratings of GMTX.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Andrew Fein HC Wainwright & Co. | Neutral | $2 | Downgrade | Mar 11, 2022 |
Marc Goodman SVB Leerink | Market Perform | $2 | Downgrade | Mar 3, 2022 |
Chris Howerton Jefferies | Hold | $1.5 | Downgrade | Mar 1, 2022 |
SVB Leerink | Outperform | $10 | Maintains | Jan 24, 2022 |
Marc Goodman SVB Leerink | Outperform | $15 | Maintains | Dec 20, 2021 |
HC Wainwright & Co. | Buy | Initiates | Dec 15, 2021 | |
Graig Suvannavejh Goldman Sachs | Buy | $18 | Maintains | Oct 6, 2021 |
SVB Leerink | Outperform | Initiates | Apr 8, 2021 | |
Jefferies | Buy | Initiates | Mar 3, 2021 | |
Goldman Sachs | Buy | Initiates | Mar 2, 2021 |
When did it IPO
2020
Staff Count
0
Country
United States
Sector/Industry
/
CEO
Market Cap
$519.2M
In 2023, GMTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GMTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of FS Development Corp., now merged with Gemini Therapeutics (NASDAQ: GMTX), urging them to seek more information.
Why It Matters - The investigation into FS Development Corp. and its merger with Gemini Therapeutics may signal potential legal issues, impacting investor confidence and stock performance for GMTX.
Summary - Disc Medicine, Inc. received FDA Orphan Drug Designation for bitopertin, aimed at treating erythropoietic protoporphyria (EPP), enhancing its development potential in hematologic diseases.
Why It Matters - Orphan Drug Designation can enhance market exclusivity and financial incentives, potentially increasing Disc Medicine's valuation and attracting investment interest in its pipeline.
Summary - Short-squeeze stocks have gained popularity, involving bets against bearish traders, reflecting a contrarian investment strategy in the current market environment.
Why It Matters - The rise of short-squeeze stocks indicates increased volatility and potential for rapid price movements, signaling opportunities and risks for investors targeting short-term gains.
Summary - Disc Medicine has initiated the Phase 2 AURORA study to evaluate bitopertin as a treatment for adults with EPP, focusing on safety and efficacy. Top-line data is expected in 2023.
Why It Matters - The AURORA study's results could influence Disc Medicine's stock value, reflecting investor sentiment on the potential success of bitopertin as a treatment for EPP.
Summary - Halper Sadeh LLC is investigating Gemini Therapeutics, Inc. for potential securities law violations related to its merger with Disc Medicine, Inc., where Gemini shareholders will retain 28% ownership.
Why It Matters - The investigation into Gemini Therapeutics' merger with Disc Medicine raises concerns over potential legal issues and shareholder rights, impacting investor confidence and stock performance.
Summary - Halper Sadeh LLP is investigating Seacoast Banking Corporation (NASDAQ: SBCF) for potential securities law violations related to its merger with Professional Holding Corp., which involves a stock exchange agreement.
Why It Matters - Investigations into potential securities law violations can indicate risks for shareholders, impacting stock performance and investor confidence in the involved companies.